Sensei Biotherapeutics (NASDAQ:SNSE) reported quarterly losses of $(131.45) per share which missed the analyst consensus estimate of $(0.62) by 21101.61 percent. This is a 2334.26 percent decrease over losses of $(5.40) per share from the same period last year.